Core--National Cell Procuremen

国家造血祖细胞处理核心的具体目标与之前的PEGT资助期相似，为NIH资助的研究人员提供大量富集的人类造血干细胞或其他细胞群，以促进他们的基础研究和临床前研究。核心将通过首先采购足够量的起始材料进行大规模加工和细胞选择来实现这一目标。核心运作的捐助者招募计划，以获得G-CSF动员和非动员收集正常志愿者，并获得尸体骨髓从西北组织中心和国家疾病研究交流。核心处理这些集合以获得大量富集的细胞亚群，提供的选择类型包括CD 34， CD 14、CD 19、CD 22、CDS、CD 4或CDS。Core通过3色或4色流式细胞术表征这些细胞，冷冻保存等分试样用于长期储存，并将组件运送给请求的研究者。在之前的PEGT期间，Core对CD 34进行了80多次大规模富集，平均最终纯度>90%，产率为60%。还对CD 14（n=40）和T细胞（n=20）进行了额外的选择，最终纯度和产率甚至更高。核心已经向来自30多个机构的60多名不同的研究人员分发了3,500多瓶富集细胞，相对于商业供应商，成本大大降低。总之，该核心将继续提供独特和关键的服务，以支持NIH资助的研究，为研究人员提供大量的富集细胞群， 体外实验、动物模型测试和临床前评估。

The specific aims of the National Hematopoietic Progenitor Cell Processing Core remain similar to those from the previous PEGT grant period, to provide NIH-funded investigators with large numbers of enriched human hematopoietic stem cells or other cell populations to facilitate their basic research and pre-clinical studies. The Core will accomplish this by first procuring sufficient amounts of starting material for large-scale processing and cell selection. The Core operates a donor recruitment program to obtain G-CSF mobilized and non-mobilized collections from normal volunteers, and also obtains cadaveric bone marrow from the Northwest Tissue Center and National Disease Research Interchange. The Core processes these collections to obtain large numbers of enriched cell subsets, the types of selections offered include CD34, CD14, CD19, CD22, CDS, CD4, or CDS. The Core characterizes these cells by 3 or 4-color flow cytometry, cryopreserves aliquots for long-term storage, and ships components to requesting investigators. During the previous PEGT the Core performed over 80 large-scale enrichments for CD34, with average final purities >90% and yields of 60%. Additional selections for CD14 (n=40) and T-cells (n=20) have also been performed, with even higher final purities and yields. The Core has distributed over 3,500 vials of enriched cells to more than 60 different investigators from more than 30 institutions, at a greatly reduced cost relative to commercial suppliers. In summary, this Core will continue to provide a unique and critical service in support of NIH funded research, supplying investigators with large numbers of enriched cell populations for in vitro experimentation, animal model testing, and pre-clinical evaluations.